Human Albumin Csl Behring

Human Albumin CSL Behring is a prescription‑only solution for injection that contains human plasma protein (human albumin) as its active ingredient. The product is supplied in a sterile aqueous solution, with the exact concentration varying by market, and is manufactured for use in the European Union. It is classified as a plasma‑derived volume expander and is typically used in hospital settings for patients requiring rapid plasma volume restoration.

Human Albumin CSL Behring is indicated for clinical situations where an increase in plasma oncotic pressure and intravascular volume is required.

- Treatment of hypovolemia due to burns, trauma, or major surgery. - Management of hypoalbuminemia associated with liver disease, nephrotic syndrome, or malnutrition. - Support during plasma exchange procedures and extracorporeal circulation. - Adjunct therapy for patients with severe sepsis or septic shock when fluid resuscitation is needed. - Volume replacement in cardiopulmonary bypass or hemodialysis when conventional crystalloids are insufficient.

Adverse reactions to Human Albumin CSL Behring are generally infrequent but can range from mild to severe.

Common: - Mild fever or chills during or shortly after infusion. - Transient hypotension or hypertension. - Headache or dizziness. - Nausea or mild gastrointestinal discomfort. - Local irritation at the infusion site. - Flushing or feeling of warmth. - Mild rash or pruritus.

Serious: - Anaphylactic or severe allergic reactions, including urticaria and bronchospasm. - Volume overload leading to pulmonary edema or congestive heart failure. - Hemolysis or renal impairment in susceptible patients. - Transmission of infectious agents, although risk is extremely low with modern manufacturing. - Thromboembolic events due to increased viscosity. - Severe electrolyte disturbances such as hypernatremia. - Acute respiratory distress syndrome (ARDS) in rare cases.

Healthcare professionals should observe specific precautions when prescribing or administering Human Albumin CSL Behring to minimize risk and ensure appropriate use.

- Assess fluid status and cardiac function before infusion to avoid overload. - Use caution in patients with renal impairment or severe liver disease. - Monitor vital signs and weight during and after administration. - Adjust dose in individuals with known hypersensitivity to albumin or plasma derivatives. - Avoid rapid infusion rates; administer over the recommended time frame. - Consider the risk of electrolyte imbalance, especially sodium, in patients on restrictive diets. - Document lot number and expiration date to trace product quality.

Human Albumin CSL Behring may interact with other medications or solutions, requiring attention to compatibility and physiological effects.

Avoid: - Co‑administration with other volume expanders that may cause fluid overload. - Simultaneous infusion of hypertonic saline solutions that could exacerbate hypernatremia. - Use with blood products containing incompatible preservatives.

Use with caution: - Diuretics, as they may alter fluid balance and increase risk of hypovolemia. - Vasopressor agents, because changes in intravascular volume can affect hemodynamic response. - Anticoagulants, since rapid volume expansion may influence coagulation parameters. - Nephrotoxic drugs, given the potential for renal stress in volume‑overloaded states.